Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 02, 2021

Biomarker Analyses of Patients With Metastatic TNBC Treated With Sacituzumab Govitecan vs Chemotherapy

Annals of Oncology


Additional Info

Annals of Oncology
Biomarker Analyses in the Phase III ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients With Metastatic Triple-Negative Breast Cancer
Ann. Oncol 2021 Sep 01;32(9)1148-1156, A Bardia, SM Tolaney, K Punie, D Loirat, M Oliveira, K Kalinsky, A Zelnak, P Aftimos, F Dalenc, S Sardesai, E Hamilton, P Sharma, S Recalde, EC Gil, T Traina, J O'Shaughnessy, J Cortes, M Tsai, L Vahdat, V Diéras, LA Carey, HS Rugo, DM Goldenberg, Q Hong, M Olivo, LM Itri, SA Hurvitz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading